Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Atomic Force Microscopy Reveals Cell Stiffness as Potential Biomarker

By LabMedica International staff writers
Posted on 24 Oct 2012
New findings reveal that cell stiffness could be potential evidence for clinicians as they look for and treat cancerous cells before they are able to metastasize. More...
The research demonstrated that highly metastatic ovarian cancer cells are several times softer than less metastatic ovarian cancer cells.

Georgia Institute of Technology (Georgia Tech; Atlanta, USA) assistant professor Dr. Todd Sulchek and PhD student Wenwei Xu used technology called atomic force microscopy (AFM) to examine the mechanical characteristics of various ovarian cell lines. A soft mechanical probe “tapped” healthy, malignant, and metastatic ovarian cells to measure their stiffness.

The study‘s findings were published October 4, 2012, in the journal PLoS One. “In order to spread, metastatic cells must force themselves into the bloodstream. As a result, they must be highly deformable and softer,” said Dr. Sulchek, a faculty member in the George W. Woodruff School of Mechanical Engineering. “Our results indicate that cell stiffness may be a useful biomarker to evaluate the relative metastatic potential of ovarian and perhaps other types of cancer cells.”

Just as earlier research on other types of epithelial cancers have indicated, Dr. Sulchek also discovered that cancerous ovarian cells are generally softer and display lower intrinsic variability in cell stiffness than nonmalignant cells. Dr. Sulchek’s lab collaborated with Prof. John McDonald, who is also director of Georgia Tech’s newly established Integrated Cancer Research Center. “This is a good example of the kinds of discoveries that only come about by integrating skills and knowledge from traditionally diverse fields such as molecular biology and bioengineering,” said Prof. McDonald. “Although there are a number of developing methodologies to identify circulating cancer cells in the blood and other body fluids, this technology offers the added potential to rapidly determine if these cells are highly metastatic or relatively benign.”

Dr. Sulchek and Prof. McDonald hope that, when further modified, this technology could offer a great benefit to clinicians in the creation of optimal chemotherapies, for ovarian cancer patients and patients of other types of cancer.

Related Links:

Georgia Institute of Technology



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
HPV Molecular Test
BD Onclarity HPV Assay
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.